FDA approved drugs with antiviral activity against SARS-CoV-2 : From structure-based repurposing to host-specific mechanisms
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
The continuing heavy toll of the COVID-19 pandemic necessitates development of therapeutic options. We adopted structure-based drug repurposing to screen FDA-approved drugs for inhibitory effects against main protease enzyme (Mpro) substrate-binding pocket of SARS-CoV-2 for non-covalent and covalent binding. Top candidates were screened against infectious SARS-CoV-2 in a cell-based viral replication assay. Promising candidates included atovaquone, mebendazole, ouabain, dronedarone, and entacapone, although atovaquone and mebendazole were the only two candidates with IC50s that fall within their therapeutic plasma concentration. Additionally, we performed Mpro assays on the top hits, which demonstrated inhibition of Mpro by dronedarone (IC50 18 µM), mebendazole (IC50 19 µM) and entacapone (IC50 9 µM). Atovaquone showed only modest Mpro inhibition, and thus we explored other potential mechanisms. Although atovaquone is Dihydroorotate dehydrogenase (DHODH) inhibitor, we did not observe inhibition of DHODH at the respective SARS-CoV-2 IC50. Metabolomic profiling of atovaquone treated cells showed dysregulation of purine metabolism pathway metabolite, where ecto-5'-nucleotidase (NT5E) was downregulated by atovaquone at concentrations equivalent to its antiviral IC50. Atovaquone and mebendazole are promising candidates with SARS-CoV-2 antiviral activity. While mebendazole does appear to target Mpro, atovaquone may inhibit SARS-CoV-2 viral replication by targeting host purine metabolism.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:162 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 162(2023) vom: 15. Juni, Seite 114614 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ahmed, Mahmoud S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.05.2023 Date Revised 22.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2023.114614 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355723492 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355723492 | ||
| 003 | DE-627 | ||
| 005 | 20231226064939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2023.114614 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355723492 | ||
| 035 | |a (NLM)37068330 | ||
| 035 | |a (PII)S0753-3322(23)00402-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ahmed, Mahmoud S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a FDA approved drugs with antiviral activity against SARS-CoV-2 |b From structure-based repurposing to host-specific mechanisms |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.05.2023 | ||
| 500 | |a Date Revised 22.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a The continuing heavy toll of the COVID-19 pandemic necessitates development of therapeutic options. We adopted structure-based drug repurposing to screen FDA-approved drugs for inhibitory effects against main protease enzyme (Mpro) substrate-binding pocket of SARS-CoV-2 for non-covalent and covalent binding. Top candidates were screened against infectious SARS-CoV-2 in a cell-based viral replication assay. Promising candidates included atovaquone, mebendazole, ouabain, dronedarone, and entacapone, although atovaquone and mebendazole were the only two candidates with IC50s that fall within their therapeutic plasma concentration. Additionally, we performed Mpro assays on the top hits, which demonstrated inhibition of Mpro by dronedarone (IC50 18 µM), mebendazole (IC50 19 µM) and entacapone (IC50 9 µM). Atovaquone showed only modest Mpro inhibition, and thus we explored other potential mechanisms. Although atovaquone is Dihydroorotate dehydrogenase (DHODH) inhibitor, we did not observe inhibition of DHODH at the respective SARS-CoV-2 IC50. Metabolomic profiling of atovaquone treated cells showed dysregulation of purine metabolism pathway metabolite, where ecto-5'-nucleotidase (NT5E) was downregulated by atovaquone at concentrations equivalent to its antiviral IC50. Atovaquone and mebendazole are promising candidates with SARS-CoV-2 antiviral activity. While mebendazole does appear to target Mpro, atovaquone may inhibit SARS-CoV-2 viral replication by targeting host purine metabolism | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Purine Metabolism | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Structure-based drug repurposing | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a entacapone |2 NLM | |
| 650 | 7 | |a 4975G9NM6T |2 NLM | |
| 650 | 7 | |a Dihydroorotate Dehydrogenase |2 NLM | |
| 650 | 7 | |a Dronedarone |2 NLM | |
| 650 | 7 | |a JQZ1L091Y2 |2 NLM | |
| 650 | 7 | |a Atovaquone |2 NLM | |
| 650 | 7 | |a Y883P1Z2LT |2 NLM | |
| 650 | 7 | |a Mebendazole |2 NLM | |
| 650 | 7 | |a 81G6I5V05I |2 NLM | |
| 650 | 7 | |a Purines |2 NLM | |
| 650 | 7 | |a Protease Inhibitors |2 NLM | |
| 700 | 1 | |a Farag, Ayman B |e verfasserin |4 aut | |
| 700 | 1 | |a Boys, Ian N |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Menendez-Montes, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Ngoc Uyen Nhi |e verfasserin |4 aut | |
| 700 | 1 | |a Eitson, Jennifer L |e verfasserin |4 aut | |
| 700 | 1 | |a Ohlson, Maikke B |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Wenchun |e verfasserin |4 aut | |
| 700 | 1 | |a McDougal, Matthew B |e verfasserin |4 aut | |
| 700 | 1 | |a Mar, Katrina |e verfasserin |4 aut | |
| 700 | 1 | |a Thet, Suwannee |e verfasserin |4 aut | |
| 700 | 1 | |a Ortiz, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Soo Young |e verfasserin |4 aut | |
| 700 | 1 | |a Solmonson, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Noelle S |e verfasserin |4 aut | |
| 700 | 1 | |a Lemoff, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a DeBerardinis, Ralph J |e verfasserin |4 aut | |
| 700 | 1 | |a Schoggins, John W |e verfasserin |4 aut | |
| 700 | 1 | |a Sadek, Hesham A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 162(2023) vom: 15. Juni, Seite 114614 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:162 |g year:2023 |g day:15 |g month:06 |g pages:114614 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2023.114614 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 162 |j 2023 |b 15 |c 06 |h 114614 | ||